Related references
Note: Only part of the references are listed.Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Edouard Louis et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)
Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
Edo H. J. Savelkoul et al.
INFLAMMATORY BOWEL DISEASES (2023)
Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study
Meghan Gibson et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2023)
Risk Factors of Cancer in Pediatric-Onset Inflammatory Bowel Disease in Denmark and Finland
Mikkel Malham et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2023)
780 ANTI-TNF IN COMBINATION WITH LOW DOSE METHOTREXATE OUTPERFORMS ANTI-TNF MONOTHERAPY IN PATIENTS WITH PEDIATRIC CROHN'S DISEASE INITIATING ADALIMUMAB BUT NOT INFLIXIMAB
Michael Kappelman et al.
Gastroenterology (2023)
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael et al.
Lancet Gastroenterology & Hepatology (2022)
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations
Ryan C. Ungaro et al.
INFLAMMATORY BOWEL DISEASES (2022)
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
Konstantinos Papamichael et al.
BMJ OPEN (2022)
Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update
Patrick F. van Rheenen et al.
JOURNAL OF CROHNS & COLITIS (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays
Rachel Nice et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis
Hillary Moore et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
Hanna van Rheenen et al.
PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION (2020)
Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
Sara Lega et al.
INFLAMMATORY BOWEL DISEASES (2019)
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis
Jean-Frederic Colombel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways
Bing Huang et al.
CELL (2019)
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
David Drobne et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial
Thomas Van Stappen et al.
GUT (2018)
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Siddharth Singh et al.
JOURNAL OF CROHNS & COLITIS (2018)
Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Dan Turner et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
JOURNAL OF CROHNS & COLITIS (2018)
Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease
Julianna Cheng et al.
INFLAMMATORY BOWEL DISEASES (2017)
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L. Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna et al.
LANCET (2015)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
Arie Levine et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2014)
Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions
Dan Turner et al.
INFLAMMATORY BOWEL DISEASES (2012)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study
Dan Turner et al.
GASTROENTEROLOGY (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
